|
gptkbp:instanceOf
|
gptkb:drug
synthetic cannabinoid
|
|
gptkbp:approvedBy
|
gptkb:FDA
1985
|
|
gptkbp:ATCCode
|
gptkb:A04AD11
|
|
gptkbp:brand
|
gptkb:Cesamet
|
|
gptkbp:CASNumber
|
gptkb:51022-71-6
|
|
gptkbp:chemicalClass
|
Cannabis
synthetic tetrahydrocannabinol derivative
|
|
gptkbp:controlledSubstanceSchedule
|
gptkb:Schedule_II_(US)
|
|
gptkbp:developedBy
|
gptkb:Eli_Lilly_and_Company
|
|
gptkbp:eliminationHalfLife
|
2 hours
|
|
gptkbp:excretion
|
urine
feces
|
|
gptkbp:hasMolecularFormula
|
C24H36O3
|
|
https://www.w3.org/2000/01/rdf-schema#label
|
nabilone
|
|
gptkbp:legalStatus
|
prescription only
|
|
gptkbp:mechanismOfAction
|
cannabinoid receptor agonist
|
|
gptkbp:metabolism
|
hepatic
|
|
gptkbp:molecularWeight
|
372.54 g/mol
|
|
gptkbp:pregnancyCategory
|
C (US)
|
|
gptkbp:PubChem_CID
|
4413
4261
|
|
gptkbp:relatedTo
|
gptkb:dronabinol
cannabis
|
|
gptkbp:routeOfAdministration
|
oral
|
|
gptkbp:sideEffect
|
dizziness
drowsiness
euphoria
hallucinations
dry mouth
|
|
gptkbp:synonym
|
gptkb:(±)-nabilone
gptkb:nabilona
|
|
gptkbp:UNII
|
gptkb:6M3C89ZY6R
|
|
gptkbp:usedFor
|
chemotherapy-induced nausea and vomiting
|
|
gptkbp:bfsParent
|
gptkb:THC
|
|
gptkbp:bfsLayer
|
6
|